

3/8/2017; Page 1

Т

Suggested Formula	Azithromycin 200 mg/5 mL Oral Liquid (Suspension, 100 mL)	FIN	F 006 142v3
----------------------	---	-----	-------------

SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC #	Supplier	Lot Number	Expiry Date
Azithromycin (Dihydrate), USP	TBD					
Glycerin, USP	20.0	mL				
Cherry Flavor (Artificial)	0.3	mL				
Banana Cream Flavor	0.5	mL				
Medisca Oral Mix (Flavored Suspending Vehicle)	35.0	mL	œ			
Medisca Oral Mix (Flavored Suspending Vehicle)	q.s. to 100.0	mL	cX			
Sodium Hydroxide 10% Solution	As required					
Hydrochloric Acid 10% Solution	As required			1		

SPECIAL PREPARATORY CONSIDERATIONS

Ingredient-Specific Information

Hygroscopic (protect from moisture whenever possible):

Suggested Preparatory Guidelines

Non-Sterile Preparation

Sterile Preparation

Processing Error / Testing Considerations:	To account for processing error and pH testing considerations during preparation, it is suggested to measure an additional 5 to 9% of the required quantities of ingredients.
Special Instruction:	Protective apparel, such as a lab coat, disposable gloves, eyewear and face-masks should always be worn.
	This procedure requires the use of very small quantities of ingredients. All calculations and preparation techniques must be verified before dispensing the final product.

Glycerin



3/8/2017; Page 2

Suggested Formula	Azithromycin 200 mg/5 mL Oral Liquid (Suspension, 100 mL)	FIN	F 006 142v3	
----------------------	---	-----	-------------	--

SUGGESTED PREPARATION (for 100 mL)

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor ^(*) :	Processing Error	Qty. to measure
Azithromycin (Dihydrate), USP	TBD				
Glycerin, USP §	20.0	mL			
Cherry Flavor (Artificial)	0.3	mL	R		
Banana Cream Flavor	0.5	mL	5		
Medisca Oral Mix (Flavored Suspending Vehicle)	35.0	mL	14		
Medisca Oral Mix (Flavored Suspending Vehicle)	q.s. to 100.0	mL	4		
Sodium Hydroxide 10% Solution	As required		0		
Hydrochloric Acid 10% Solution	As required	4			

§ Weigh / measure just prior to use.

* Takes into account increased batch size conversions and density conversions, if required.



3/8/2017; Page 3

Suggested Formula			F 006 142v3
	Preparatory Instruction		
I. Ingro	edient quantification:		
A. I	Determine the potency of Azithromycin (Dihydrate) based on the certificate of analysis:		
		100	%
P	AINUS		
V	Vater content (from certificate of analysis)		%
I	DIVIDED BY	100)
I	EQUALS		
(Quantity of water free Azithromycin (Dihydrate), in decimal		
N	AULTIPLIED BY		
I	Assay on anhydrous basis result (from certificate of analysis)		μ <i>g</i> /mg
Ν	AULTIPLIED BY (Multiplication factor – μg to grams /mg to grams)	0.00	01
H	EQUALS		
i	Potency of Azithromycin (Dihydrate) in g/g		



3/8/2017; Page 4

Suggested Formula			FIN	F 006 142v3			
2.	Ingr	redient quantification:					
	A. Determine the quantity (in g) of Azithromycin (Dihydrate) required to make a 100 mL batch of Azithromycin 200 mg/5 mL Oral Liquid:						
		Quantity of Azithromycin (Dihydrate) required for 100 mL		4.000 g			
		DIVIDED BY					
		Potency of Azithromycin (Dihydrate) in g/g (Step 1Ai)	_				
		EQUALS					
		i. Quantity of Azithromycin (Dihydrate) needed for 100 mL	_	g			
		MULTIPLED BY					
		Processing error adjustments (5 to 9%)	1	.05 to 1.09			
		EQUALS					
		ii. Quantity of Azithromycin (Dihydrate) needed plus processing error adjustments	_	g			
3.	<u>Pow</u>	der-liquid preparation:					
	A.	Triturate the Azithromycin (Dihydrate) (amount determined from Step 2Aii) to form a fin	e, hon	ogeneous powder.			
	В.	Levigate the fine, homogeneous powder (Step 3A) with the Glycerin.					
		End result: Homogeneous liquid-like dispersion.					
4.	Med	lium integration:					
	A.	In the given order, sequentially add the following ingredients to the Oral Mix (Flavored S	uspend	ling Vehicle):			
		-Cherry Flavor (Artificial) -Banana Cream Flavor					
		-Homogeneous liquid-like dispersion (Step 3B)					
		Specifications: Continuously mix, using high-shear mixing techniques.					
		End result: Homogeneous liquid-like dispersion.					
		Note: Add the next ingredient, once the previous one has been completely added and disp	persed.				



3/8/2017; Page 5

	ggested formulaAzithromycin 200 mg/5 mL Oral Liquid (Suspension, 100 mL)FINF 006 142v3						
5.	Filling to volume: A. Add additional Oral Mix (Flavored Suspending Vehicle) to the mixture (Step 4A) to fill to the required batch size (100.0 mL <i>plus</i> processing error adjustments). Specifications: Continuously mix, using high-shear mixing techniques. End result: Homogeneous liquid-like dispersion.						
6.	pH testing: A. Draw an appropriate amount of the mixture (Step 5A). B. Test the pH of the sample. It should lie between 9 and 11. C. If the pH < 9, carefully add the Sodium Hydroxide 10% Solution in a dropwise manner to the mixture:						
7.	Product transfer: A. Transfer the final product into the specified dispensing container (see "Packaging requirements"). Note: Continuously mix the final product during the transfer process into the recommended dispensing containers in order to maintain homogeneity.						



3/8/2017; Page 6

Suggested Formula	Azithromycin 200 mg/5 mL Oral Liquid (Suspension, 100 mL)	FIN	F 006 142v3	
----------------------	---	-----	-------------	--

SUGGESTED PRESENTATION

	Estimated Beyond-Use Date		10 days, refrigerated.	Packa Requirem		 Tightly closed dispensing bottle. To be administered with a metered-dose measuring device. 	
		1	Use as directed. Do not exceed dose.	l prescribed	5	Cap tightly after use.	
		2	Keep out of reach of children.		6	Shake well before use.	
	Auxiliary Labels	3	Consult your health care practit other prescription or over medications are currently being prescribed for future use.	-the-counter	7	Keep refrigerated. Do not freeze.	
		4	Do not take with alcohol, tranquilizers or other CNS depre	1	8	May impair mental and/or physical ability. Use care when operating a car or machinery.	
	Pharmacist Instructions Add any auxiliary labels specific to the active to the dispensing container as deemed necessary.						
	Patient Instructions	Contact your pharmacist in the event of adverse reactions					



3/8/2017; Page 7

	Suggeste Formu	FIN	F 006 142v3						
E	EFERENCES								
	1. Su	Suspensions. In: Allen, LV, Jr. The Art, Science and Technology of Pharmaceutical Compounding Fourth Edition.							

					\sim		•
ĸ		-	ы	N		ES	÷.
1		_	I N		$\mathbf{\nabla}$	_	

1.	Suspensions. In: Allen, LV, Jr. <i>The Art, Science and Technology of Pharmaceutical Compounding Fourth Edition.</i> American Pharmaceutical Association; 2012: 239.
2.	Zithromax Cream. In: Canadian Pharmacists Association. Compendium of Pharmacists and Specialties, 2014: 3229.
3.	Glycerin. In: Rowe RC. <i>Handbook of Pharmaceutical Excipients</i> , 7 th <i>Edition</i> . American Pharmaceutical Association; 2012: 324.
4.	Azithromycin. In: Sweetman SC, ed. <i>Martindale: The Complete Drug Reference, 36th Edition</i> . London, England: The Pharmaceutical Press; 2009: 207.
5.	Azithromycin (Monograph). In: O'Neil MJ. <i>The Merck Index 15th Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2013: Monograph #907.
6.	Azithromycin. In: Trissel LA. Trissel's Stability of Compounded Formulations, 5 th Edition. American Pharmaceutical Association; 2012: 56.
7.	Azithromycin (Monograph). United States Pharmacopeia XXXVII / National Formulary 32. Rockville, MD. US Pharmacopeial Convention, Inc. 2014: 1886.
8.	Azithromycin Systemic. Thomson Micromedex. USP DI – Drug Information for the Health Care Professional, 26 th Edition. Taunton, MA: US Pharmacopeial Convention, Inc; 2006: 505.
9.	USP <795>. United States Pharmacopeia XXXVII / National Formulary 32. Rockville, MD. US Pharmacopeial Convention, Inc. 2014: 403.

DISCLAIMER: MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAS PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY, SCHEDULING OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW.